Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients

Exclusion Criteria

• •a previous cardiovascular event: cardiac arrhythmias, cardiac arrest, angina or acute myocardial infarction, stroke, carotid stenosis of more than 50%, peripheral vascular arteriopathy documented
• •hospitalization for any cause in the last three months prior to inclusion in the study allergy of acetyl-salicylic acid
• •coagulopathy from any cause
• •thrombocytopenia \<150,000 platelets
• •liver disease from any cause
• •Infection by hepatitis B virus, hepatitis C or HIV
• •immunosuppressive treatment within 12 weeks before inclusion in the study
• •Major bleeding events including gastrointestinal bleeding and brain hemorrhage.
• •hemoglobinopathies (eg sickle cell disease or thalassemia of any kind)
• •active malignancy (except non-melanoma skin cancer). May be included in the study patients with malignant neoplasia who have remained disease-free for at least the previous 5 years.
• •uncontrolled inflammatory disease or symptomatic (eg rheumatoid arthritis, lupus, Chrom disease or bowel inflammatory disease)
• •hemolysis
• •treatment with oral anticoagulation and / or antiplatelet therapy prior.
• •poorly controlled hypertension (\> 160/90 mm Hg) -pregnancy or breast-
• •women of childbearing potential not using effective contraception.